Plumb Pharmaceuticals, Inc.
Plumb Pharmaceuticals is a Madison, Wisconsin-based pharmaceutical company developing extended-release formulations of FDA-approved drugs. Its liposome-based drug delivery approach uses loading-base exchange to load compounds and is intended to support drug release over periods measured in months. Its initial product focus is an injectable naltrexone formulation for opioid and alcohol use disorder.
Industries
N/A
Patents
Products
An injectable naltrexone formulation in development that uses liposomal delivery. The described intended effective duration is approximately two months.
A platform method for forming liposomes and loading drugs into them through exchange with a loading base, with the aim of supporting prolonged release after injection. The company describes potential application to other FDA-approved compounds.
An injectable naltrexone formulation in development that uses liposomal delivery. The described intended effective duration is approximately two months.
A platform method for forming liposomes and loading drugs into them through exchange with a loading base, with the aim of supporting prolonged release after injection. The company describes potential application to other FDA-approved compounds.
Expertise Areas
- Extended-release drug delivery
- Liposomal drug formulation
- Pharmaceutical formulation development
- Medication-assisted treatment formulation
Key Technologies
- Liposomes
- Indirect drug loading
- Loading-base exchange
- Subcutaneous drug delivery
News & Updates
The company announced that it had secured seed investment from the Winnow Fund earlier in 2022.
The company reported receiving two issued patents covering a liposome formation method and a complementary indirect drug-loading method.
The company announced that it had secured seed investment from the Winnow Fund earlier in 2022.
The company reported receiving two issued patents covering a liposome formation method and a complementary indirect drug-loading method.